| 1 |
34821461 | Low concentrations of 17β-estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor-mediated signaling pathways. | 2022 Mar |
1 |
| 2 |
34073371 | TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer. | 2021 May 26 |
1 |
| 3 |
34681897 | Suppression of Estrogen Receptor Alpha Inhibits Cell Proliferation, Differentiation and Enhances the Chemosensitivity of P53-Positive U2OS Osteosarcoma Cell. | 2021 Oct 18 |
2 |
| 4 |
34779146 | TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. | 2021 Dec |
1 |
| 5 |
32722075 | Tamoxifen and the PI3K Inhibitor: LY294002 Synergistically Induce Apoptosis and Cell Cycle Arrest in Breast Cancer MCF-7 Cells. | 2020 Jul 24 |
1 |
| 6 |
32987137 | Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer. | 2020 Dec 28 |
1 |
| 7 |
33177647 | Coffee decoction enhances tamoxifen proapoptotic activity on MCF-7 cells. | 2020 Nov 11 |
3 |
| 8 |
30535478 | TP53 upregulates α‑smooth muscle actin expression in tamoxifen‑resistant breast cancer cells. | 2019 Feb |
1 |
| 9 |
30990221 | TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer. | 2019 Nov 1 |
2 |
| 10 |
29464864 | Inferences of individual drug responses across diverse cancer types using a novel competing endogenous RNA network. | 2018 Sep |
1 |
| 11 |
29590203 | Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. | 2018 |
1 |
| 12 |
30050469 | Tamoxifen-Induced Apoptosis of MCF-7 Cells via GPR30/PI3K/MAPKs Interactions: Verification by ODE Modeling and RNA Sequencing. | 2018 |
2 |
| 13 |
30285883 | Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. | 2018 Oct 1 |
1 |
| 14 |
30504836 | Tumour-vasculature development via endothelial-to-mesenchymal transition after radiotherapy controls CD44v6+ cancer cell and macrophage polarization. | 2018 Nov 30 |
1 |
| 15 |
27888811 | The role of p53 in cancer drug resistance and targeted chemotherapy. | 2017 Jan 31 |
1 |
| 16 |
26909605 | Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. | 2016 Mar 29 |
1 |
| 17 |
25503558 | Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway. | 2015 Feb 1 |
1 |
| 18 |
25595558 | Sp1 regulates Raf/MEK/ERK-induced p21(CIP1) transcription in TP53-mutated cancer cells. | 2015 Mar |
1 |
| 19 |
26365581 | Activity of the antiestrogenic cajanin stilbene acid towards breast cancer. | 2015 Nov |
1 |
| 20 |
24361399 | Premature senescence in human breast cancer and colon cancer cells by tamoxifen-mediated reactive oxygen species generation. | 2014 Mar 3 |
5 |
| 21 |
24853176 | MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases. | 2014 Jun 10 |
1 |
| 22 |
23077249 | Estrogen receptor prevents p53-dependent apoptosis in breast cancer. | 2012 Oct 30 |
1 |
| 23 |
20549698 | p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. | 2011 Apr 15 |
1 |
| 24 |
21191649 | P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. | 2011 Nov |
2 |
| 25 |
21547354 | Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity. | 2011 Jun |
1 |
| 26 |
22041887 | Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. | 2011 Nov 15 |
1 |
| 27 |
30780881 | Predicting response: identifying molecular determinants of endocrine response and resistance in breast cancer. | 2011 Sep |
1 |
| 28 |
19806450 | Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy. | 2010 Jun |
3 |
| 29 |
20696891 | Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. | 2010 Aug 24 |
2 |
| 30 |
21119367 | Expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen. | 2010 Dec |
2 |
| 31 |
19351845 | Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. | 2009 Apr 15 |
1 |
| 32 |
19460356 | Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. | 2009 Jul 24 |
5 |
| 33 |
18377724 | CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs. | 2008 Mar 31 |
1 |
| 34 |
18397472 | G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells. | 2008 May |
2 |
| 35 |
18425390 | Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma. | 2008 May |
5 |
| 36 |
18497060 | IRF-1 promotes apoptosis in p53-damaged basal-type human mammary epithelial cells: a model for early basal-type mammary carcinogenesis. | 2008 |
4 |
| 37 |
20020938 | CAS Enhances Chemotherapeutic Drug-Induced p53 Accumulation and Apoptosis: Use of CAS for High-Sensitivity Anticancer Drug Screening. | 2008 Jan |
1 |
| 38 |
17235397 | Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. | 2007 Feb |
1 |
| 39 |
17307334 | Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells. | 2007 Jun |
1 |
| 40 |
17663174 | [Response to tamoxifen in estrogen receptor-positive cell line MCF-7 is independent of p53 expression]. | 2007 |
2 |
| 41 |
17786323 | Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. | 2007 Oct |
1 |
| 42 |
16609366 | p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. | 2006 May |
1 |
| 43 |
18603889 | Evaluation of endometrial changes and p53 expression in tamoxifen treated women: comparison of various methods. | 2006 Apr-Jun |
1 |
| 44 |
15832264 | Differences in oestrogen and progesterone receptors, HER-2, p53 expression and proliferation in ductal breast cancers in relation to histopathological grade. | 2005 Feb |
1 |
| 45 |
15938631 | Investigating DNA adduct-targeted mutagenicity of tamoxifen: preferential formation of tamoxifen-DNA adducts in the human p53 gene in SV40 immortalized hepatocytes but not endometrial carcinoma cells. | 2005 Jun 14 |
2 |
| 46 |
12684392 | Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. | 2003 Apr |
4 |
| 47 |
14633737 | Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. | 2003 Nov 15 |
1 |
| 48 |
12088100 | Changes in apoptosis, mitosis, Her-2, p53 and Bcl2 expression in breast carcinomas after short-term tamoxifen treatment. | 2002 |
2 |
| 49 |
12376463 | Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin induced-apoptosis: role of TGF-beta1. | 2002 Oct |
1 |
| 50 |
12530022 | PTEN expression in tamoxifen-associated endometrial cancers. | 2002 Sep-Oct |
1 |